Trump Administration Drafts 100% Tariff on Patented Drug Imports, Threatening Pharma Supply Chains

A draft executive order prepared by the Trump administration proposes a staggering 100% tariff on imports of certain patented medications and their active ingredients. The move, which could be announced imminently, represents a direct and aggressive escalation in trade policy targeting the pharmaceutical sector. The draft, obtained by STAT reporter Daniel Payne, signals a potential seismic shift in the cost and sourcing of critical medicines, though timelines and final plans remain fluid.

The proposed tariff would specifically target patented drugs and their key components entering the U.S. market. This action, if enacted, would impose severe financial pressure on pharmaceutical companies reliant on global manufacturing networks, potentially disrupting supply chains and increasing costs. The order's existence reveals a concrete policy pathway being actively considered, moving beyond rhetoric to a tangible regulatory threat.

The immediate implications center on heightened uncertainty for drug manufacturers, distributors, and payers. The policy would force a rapid reassessment of sourcing strategies and could trigger retaliatory trade measures. For the FDA, which is already under scrutiny for transparency issues and its approach to AI in devices, this external trade pressure adds another layer of complexity to its regulatory environment. The pharmaceutical industry now faces the dual challenges of navigating a volatile trade landscape while competing in a market transformed by new entrants like Eli Lilly's recently approved oral obesity drug.